Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares

Key Points

• Representative Gilbert Ray Cisneros, Jr. purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) worth between $1,001 and $15,000, as disclosed on September 12th.
• Ultragenyx Pharmaceutical's stock has recently shown positive performance, trading at $29.48 with a market capitalization of $2.84 billion and reporting a 13.2% revenue increase compared to the same quarter last year.
• Recent insider transactions include an executive selling shares at an average price of $31.17, indicating a 3.24% reduction in ownership, while institutional investors have increased their stakes significantly in the company.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on August 8th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Chart Industries NYSE: GTLS on 9/2/2025.
• Purchased $1,001 - $15,000 in shares of Avient NYSE: AVNT on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/27/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Intapp NASDAQ: INTA on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of APi Group NYSE: APG on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Waters NYSE: WAT on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 8/26/2025.
• Sold $1,001 - $15,000 in shares of Fortive NYSE: FTV on 8/26/2025.

Ultragenyx Pharmaceutical Stock Performance

RARE traded up $0.48 during midday trading on Tuesday, hitting $29.48. The company had a trading volume of 2,063,623 shares, compared to its average volume of 1,313,552. The company has a market capitalization of $2.84 billion, a PE ratio of -5.33 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a twelve month low of $25.81 and a twelve month high of $59.90. The firm's 50-day simple moving average is $29.49 and its 200-day simple moving average is $34.26.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to analysts' expectations of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the company's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares in the company, valued at approximately $573,712.16. This represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the company's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the transaction, the executive vice president owned 73,271 shares in the company, valued at $2,283,857.07. This trade represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 1,061.9% in the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 669 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at $55,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at $57,000. Finally, Headlands Technologies LLC acquired a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at $59,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Wells Fargo & Company lowered their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research report on Thursday, July 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $105.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. Morgan Stanley reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, July 14th. Wedbush cut their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating on the stock in a research note on Monday, July 14th. Finally, Canaccord Genuity Group cut their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus target price of $81.50.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.